PAREXEL TO ADDRESS INNOVATIVE APPROACHES TO LATE STAGE DEVELOPMENT AT SUMMIT FOR CLINICAL OPS EXECUTIVES - Company to Chair Session on Electronic Health Records and Clinical Trials, Discuss Social Media in Patient Recruitment
Boston, MA, February 6, 2012—PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Ramita Tandon, Global Head, Late Phase Clinical Trials and Lars-Olof Eriksson, Ph.D., MS.c., Vice President, Global Research Operations at PAREXEL will address innovative approaches to late stage development at the Summit for Clinical Ops Executives (SCOPE), to be held February 7-9, 2012 in Miami, Florida. Attendees can learn about customized strategic and scientific solutions, provided by the PAREXEL PACE™ (Peri-Approval Clinical Excellence) group, to facilitate the transition from product development to commercialization in a seamless and cost-effective manner, by visiting the PAREXEL Booth #38 on the exhibit floor.
During SCOPE, Ms. Tandon will provide opening remarks for the session entitled “Electronic Health Records and Clinical Trials.” The session, which will be held on Tuesday, February 7 at 8:15 a.m., includes presentations from Pfizer, Incyte Corporation, and the Medicines and Healthcare products Regulatory Agency (MHRA).
Other program sessions being presented by PAREXEL experts include:
Tuesday, February 7, 4:30 p.m. and Wednesday, February 8, 4:20 p.m.
- “New Challenges Call for Innovative Approaches to Patient Recruitment and Retention for Post Marketing Trials,” in two interactive breakout discussion groups
Facilitated by Ms. Tandon and Dr. Eriksson, these interactive discussions will assist attendees in understanding how effective strategies for emerging areas, including engagement in social media and use of electronic medical records, can offer benefits to the post marketing research enterprise and patient community. They will highlight trends driving the need for cost efficient patient recruitment and retention approaches.
Wednesday, February 8, 11:35 a.m.
- “Conducting Phase IIIB/IV Clinical Trials in a Changing Drug Environment,” in the session Utilization of Patient-Level Data and Patient Reported Outcomes in Trials
Ms. Tandon will discuss industry dynamics that have placed increasing emphasis on the use of late phase clinical trial data. She will examine innovative and cost efficient tools and methodologies to conduct post marketing trials to ensure higher data quality, and accelerate better decision-making.
PAREXEL’s late phase capabilities include Phase IIIb and IV clinical trials, observational research, post approval safety surveillance programs and post-marketing pharmacovigilance, as well as health economics and outcomes research services. For more information, visit: http://www.parexel.com/services-and-capabilities/late-phase.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 11,300 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $2.0 million in the third quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 as filed with the SEC on November 9, 2011, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.